|
|
|
Insider
Information: |
Labrucherie Gil M |
Relationship: |
Chief Financial Officer |
City: |
San Carlos |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
319,155 |
|
Indirect Shares
|
94,335 |
|
|
Direct
Value |
$422,135 |
|
|
Indirect Value
|
$488,235 |
|
|
Total
Shares |
413,490 |
|
|
Total
Value |
$910,370 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
6
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
6
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-6.0
|
Percentage
Gain/Loss : |
0.0%
|
-181.1%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Nektar Therapeutics |
NKTR |
SVP, COO & CFO |
2022-05-16 |
312,905 |
2008-11-14 |
0 |
Premium* |
|
Rezolute, Inc |
RZLT |
Director |
2022-05-04 |
0 |
2022-05-04 |
53,572 |
Premium* |
|
Acelyrin, Inc. |
SLRN |
Chief Financial Officer |
2023-10-04 |
6,250 |
2023-10-04 |
40,763 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
104 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 5
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2019-02-19 |
4 |
S |
$42.39 |
$152,265 |
D/D |
(3,592) |
131,702 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2014-11-24 |
4 |
AS |
$15.04 |
$157,920 |
D/D |
(10,500) |
3,751 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
|
2019-11-18 |
4 |
S |
$17.97 |
$159,268 |
D/D |
(8,863) |
219,009 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2016-01-19 |
4 |
AS |
$14.12 |
$164,738 |
D/D |
(11,667) |
5,251 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
|
2021-02-16 |
4 |
S |
$22.37 |
$178,445 |
D/D |
(7,977) |
258,996 |
0 |
% |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2019-06-17 |
4 |
OE |
$7.21 |
$180,250 |
D/D |
25,000 |
152,935 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2019-07-10 |
4 |
OE |
$7.21 |
$180,250 |
D/D |
25,000 |
152,935 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2019-08-14 |
4 |
OE |
$7.21 |
$180,250 |
D/D |
25,000 |
152,935 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2019-09-16 |
4 |
OE |
$7.21 |
$180,250 |
D/D |
25,000 |
177,872 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
|
2019-10-15 |
4 |
OE |
$7.21 |
$180,250 |
D/D |
25,000 |
252,872 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
|
2019-11-13 |
4 |
OE |
$7.21 |
$180,250 |
D/D |
25,000 |
252,872 |
0 |
- |
|
RZLT |
Rezolute, Inc |
Director |
|
2022-05-04 |
4/A |
B |
$3.80 |
$199,998 |
I/I |
52,631 |
53,572 |
2.1 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2015-08-13 |
4 |
OE |
$6.98 |
$232,664 |
D/D |
33,333 |
38,084 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2015-07-14 |
4 |
OE |
$6.98 |
$232,671 |
D/D |
33,334 |
37,585 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2018-11-16 |
4 |
S |
$38.25 |
$249,199 |
D/D |
(6,515) |
106,544 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
|
2021-11-16 |
4 |
AS |
$13.16 |
$278,321 |
D/D |
(21,149) |
259,682 |
0 |
% |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2018-02-16 |
4 |
S |
$82.94 |
$288,382 |
D/D |
(3,477) |
99,739 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2017-11-16 |
4 |
D |
$44.23 |
$296,253 |
D/D |
(6,698) |
76,716 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2015-09-23 |
4 |
OE |
$6.46 |
$308,027 |
D/D |
44,999 |
49,750 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2015-10-06 |
4 |
OE |
$6.46 |
$308,033 |
D/D |
45,000 |
49,751 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2015-11-11 |
4 |
OE |
$6.46 |
$308,033 |
D/D |
45,000 |
49,751 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2015-12-03 |
4 |
OE |
$6.46 |
$308,040 |
D/D |
45,001 |
50,252 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2018-05-01 |
4 |
OE |
$10.69 |
$320,700 |
D/D |
30,000 |
129,739 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2018-05-02 |
4 |
OE |
$10.69 |
$320,700 |
D/D |
30,000 |
129,739 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2018-05-03 |
4 |
OE |
$10.69 |
$320,700 |
D/D |
30,000 |
129,739 |
0 |
- |
|
104 Records found
|
|
Page 3 of 5 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|